USANA Health Sciences Management

Management criteria checks 2/4

USANA Health Sciences' CEO is Jim Brown, appointed in Nov 2016, has a tenure of 7.5 years. total yearly compensation is $2.47M, comprised of 28.7% salary and 71.3% bonuses, including company stock and options. directly owns 0.05% of the company’s shares, worth €422.58K. The average tenure of the management team and the board of directors is 7.3 years and 6.2 years respectively.

Key information

Jim Brown

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage	28.7%
CEO tenure	7.5yrs
CEO ownership	0.05%
Management average tenure	7.3yrs
Board average tenure	6.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Brown's remuneration changed compared to USANA Health Sciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 30 2024	n/a	n/a	US$62m
Dec 30 2023	US$2m	US$710k	US$64m
Sep 30 2023	n/a	n/a	US$60m
Jul 01 2023	n/a	n/a	US$63m
Apr 01 2023	n/a	n/a	US$65m
Dec 31 2022	US$2m	US$624k	US$69m
Oct 01 2022	n/a	n/a	US$77m
Jul 02 2022	n/a	n/a	US$89m
Apr 02 2022	n/a	n/a	US$108m
Jan 01 2022	US$2m	US$600k	US$117m
Oct 02 2021	n/a	n/a	US$136m
Jul 03 2021	n/a	n/a	US$139m
Apr 03 2021	n/a	n/a	US$129m
Jan 02 2021	US$2m	US$599k	US$125m
Sep 26 2020	n/a	n/a	US$116m
Jun 27 2020	n/a	n/a	US$110m
Mar 28 2020	n/a	n/a	US$103m
Dec 28 2019	US$2m	US$559k	US$101m
Sep 28 2019	n/a	n/a	US$102m
Jun 29 2019	n/a	n/a	US$109m
Mar 30 2019	n/a	n/a	US$121m
Dec 29 2018	US$2m	US$534k	US$126m
Sep 29 2018	n/a	n/a	US$88m
Jun 30 2018	n/a	n/a	US$81m
Mar 31 2018	n/a	n/a	US$70m
Dec 30 2017	US$1m	US$523k	US$63m

Compensation vs Market: Jim's total compensation ($USD2.47M) is above average for companies of similar size in the German market ($USD1.30M).

Compensation vs Earnings: Jim's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Jim Brown (54 yo)

7.5yrs

Tenure

US$2,472,017

Compensation

Mr. Jim Brown has been the President of USANA Health Sciences Inc. since November 2016 and served as its Chief Operating Officer since November 2013 until October 2019. He serves as Chief Executive Officer...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin Guest	Executive Chairman	7yrs	US$3.91m	0.063% $ 534.0k
Jim Brown	CEO & President	7.5yrs	US$2.47m	0.050% $ 423.5k
G. Hekking	Chief Financial Officer	7yrs	US$1.47m	0.034% $ 289.1k
Walter Noot	Chief Operating Officer	4.6yrs	US$1.42m	no data
P. Foukas	Chief Legal Officer	5.8yrs	US$1.29m	no data
Daniel Macuga	Chief Communications & Marketing Officer	12.4yrs	US$1.15m	0.029% $ 248.2k
Myron Wentz	Founder & Chairman Emeritus	32.3yrs	no data	40.97% $ 345.7m
John Cuomo	Executive Director of Product Development & Technology	11.4yrs	no data	no data
Robert Sinnott	Chief Scientific Officer	7.8yrs	no data	no data
Patrique Richards	Executive Director of Investor Relations & Business Development	no data	no data	no data
Paul Jones	Chief People Officer	3.3yrs	US$637.78k	0.047% $ 393.8k
Ashley Collins	Executive Vice President of Marketing	no data	no data	no data

7.3yrs

Average Tenure

57yo

Average Age

Experienced Management: USJ's management team is seasoned and experienced (7.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin Guest	Executive Chairman	7yrs	US$3.91m	0.063% $ 534.0k
Myron Wentz	Founder & Chairman Emeritus	4yrs	no data	40.97% $ 345.7m
Gilbert Fuller	Lead Independent Director	15.7yrs	US$251.60k	0.0026% $ 21.5k
Peggie Pelosi	Independent Director	5.4yrs	US$231.40k	0.017% $ 146.8k
Timothy Wood	Independent Director	4.6yrs	US$218.64k	0.027% $ 230.3k
Christine Wood	Member of Scientific Advisory Council	no data	no data	no data
Monica Lewis	Member of Scientific Advisory Council	no data	no data	no data
Peter Rugg	Chairperson of Scientific Advisory Council	20.3yrs	no data	no data
Bart Moore	Member of Scientific Advisory Council	no data	no data	no data
Heather Tick	Member of Scientific Advisory Council	no data	no data	no data
Frederic Winssinger	Independent Director	8yrs	US$233.84k	0.017% $ 139.2k
J. Nixon	Independent Director	1.8yrs	US$118.10k	0.015% $ 126.6k

6.2yrs

Average Tenure

67yo

Average Age

Experienced Board: USJ's board of directors are considered experienced (6.2 years average tenure).

USANA Health Sciences Management

Management criteria checks 2/4

Key information

Recent management updates

Insider recently sold €167k worth of stock

USANA Health Sciences, Inc., Annual General Meeting, May 06, 2024

Chief Legal Officer recently sold €215k worth of stock

Chief People Officer recently sold €217k worth of stock

Insufficient new directors

Insider recently sold €736k worth of stock

Recent updates

Insider recently sold €167k worth of stock

First quarter 2024 earnings released: EPS: US$0.86 (vs US$0.95 in 1Q 2023)

USANA Health Sciences, Inc. to Report Q1, 2024 Results on Apr 30, 2024

USANA Health Sciences, Inc., Annual General Meeting, May 06, 2024

Chief Legal Officer recently sold €215k worth of stock

Full year 2023 earnings released: EPS: US$3.31 (vs US$3.60 in FY 2022)

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: US$3.30 (vs US$3.60 in FY 2022)

USANA Health Sciences, Inc. Provides Earnings Guidance for the Fiscal Year 2024

USANA Health Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Investor sentiment deteriorates as stock falls 17%

USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.59 (vs US$0.78 in 3Q 2022)

USANA Health Sciences, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Chief People Officer recently sold €217k worth of stock

USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.89 (vs US$1.00 in 2Q 2022)

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Insufficient new directors

Insider recently sold €736k worth of stock

Independent Director recently sold €149k worth of stock

First quarter 2023 earnings released: EPS: US$0.95 (vs US$1.16 in 1Q 2022)

Chairman of the Board & CEO recently sold €301k worth of stock

Kevin Guest to Transit to the Role of Executive Chairman of USANA Health Sciences, Inc., Effective July 1, 2023

Insider recently sold €108k worth of stock

Full year 2022 earnings released: EPS: US$3.59 (vs US$5.78 in FY 2021)

Usana Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for the Fiscal Year 2023

USANA Health Sciences, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Insider recently sold €76k worth of stock

USANA Health Sciences, Inc. (NYSE:USNA) acquired Rise Bar and Oola Global, LLC.

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.37 in 3Q 2021)

USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Year 2022

USANA Health Sciences, Inc. to Report Q3, 2022 Results on Oct 25, 2022

Chief People Officer recently sold €346k worth of stock

Chief Financial Officer recently sold €75k worth of stock

USANA Health Sciences, Inc. Announces Rejoining of J. Scott Nixon to Board of Directors

USANA Health Sciences, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: EPS: US$1.00 (vs US$1.89 in 2Q 2021)

USANA Health Sciences, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Insider recently sold €95k worth of stock

First quarter 2022 earnings released: EPS: US$1.15 (vs US$1.47 in 1Q 2021)

USANA Health Sciences, Inc. Revises Earnings Guidance for Fiscal Year 2022

USANA Health Sciences, Inc. to Report Q1, 2022 Results on Apr 26, 2022

USANA Health Sciences, Inc., Annual General Meeting, May 09, 2022

Chief Legal Officer recently sold €268k worth of stock

Chief Operating Officer recently sold €214k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

USANA Health Sciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Chief Sales Officer recently sold €79k worth of stock

Chief Sales Officer recently sold €110k worth of stock

Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.45 in 3Q 2020)

USANA Health Sciences, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Independent Director recently sold €51k worth of stock

Second quarter 2021 earnings released: EPS US$1.87 (vs US$1.33 in 2Q 2020)

Director recently sold €51k worth of stock

USANA Launches New Product Line

Independent Director has left the company

First quarter 2021 earnings released: EPS US$1.45 (vs US$1.24 in 1Q 2020)

USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year 2021

New 90-day high: €83.00

Full year 2020 earnings released: EPS US$5.89 (vs US$4.44 in FY 2019)

Revenue beats expectations

Insider recently sold €413k worth of stock

USANA Announces Formation of Board Sustainability Committee

Full year 2020 earnings released: EPS US$5.87 (vs US$4.44 in FY 2019)